GleamWall
中文EN

TIL Instil Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789769 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY71.9%
TTM EPS YoY73.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-19.2%
ROA-10.4%
ROIC (approx.)-21.8%
Asset turnover—

Leverage & solvency

Liabilities / assets47.6%
Debt / equity0.00x
Current ratio10.42x
Interest coverage-4.69x

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$24.74M$11.84M
SG&A expense$27.22M$44.21M
Operating income-$78.58M-$73.54M
Interest expense$5.83M$8.99M
Pretax income-$71.37M-$74.14M
Income tax$0—
Net income-$71.37M-$74.14M
EBITDA-$78.05M-$69.93M
EPS (basic)-10.70-11.39
EPS (diluted)-10.70-11.39
Weighted avg. shares (diluted)6.67M6.51M
Balance sheet
Cash & equivalents$6.64M$10.63M
Short-term investments$69.49M—
Current assets$192.42M$124.47M
PP&E, net$126,000$129.41M
Total assets$204.51M$263.57M
Current liabilities$7.03M$7.90M
Total liabilities$91.84M$94.13M
Shareholders' equity$112.67M$168.27M
Shares outstanding6.78M6.53M
Cash flow statement
Operating cash flow-$36.62M-$55.70M
Capital expenditure—$0
Free cash flow—-$55.70M
Investing cash flow$25.48M$53.97M
Financing cash flow$7.29M$1.75M
Depreciation & amortization$534,000$3.61M
Stock-based compensation$8.69M$17.26M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.